A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44

Trial Profile

A 24 Week, Prospective, Randomized, Parallel-group, Double-blind, Multi-center Study (ENA713DUS44) Comparing the Effects of Rivastigmine Patch 15 cm^2 vs. Rivastigmine Patch 5 cm^2 on ACTivities of Daily Living and CognitION in Patients With Severe Dementia of the Alzheimer's Type (ACTION) and a 24-week Open-label Extension to Study ENA713DUS44

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Jul 2015

At a glance

  • Drugs Rivastigmine (Primary)
  • Indications Alzheimer's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms ACTION
  • Sponsors Novartis
  • Most Recent Events

    • 18 Jul 2013 Results for 24 week extension phase presented at the 2013 Alzheimer's Association International Conference .
    • 27 Jun 2013 High-dose rivastigmine patch (13.3mg/24h) [Exelon] was approved by the US FDA for the treatment of all stages of Alzheimer's disease, based on the results of this pivotal trial, according to a Novartis media release.
    • 23 Mar 2013 Primary endpoint 'Severe-Impairment-Battery' has been met for high-dose patch.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top